Morocco Enhances Pharmaceutical Sector with New Production Facility
Cipla eyes next leg of growth from global biz
Cipla, Putting Social Stigma to Rest
Cipla receives final approval for generic version of Impax Laboratories, Inc.’s Albenza® (Albendazole Tablets 200mg)
Press Release Cipla Quality Chemical Industries Limited Bell Ringing and First Day of Trading on the Uganda Securities Exchange
Cipla Quality Chemical Industries Limited Bell Ringing and First Day of Trading on the Uganda Securities Exchange
CIPLA’S NEW TRIPLE COMBINATION ANTIRETROVIRAL DRUG APPROVED
Cipla’s New Triple Combination Antiretroviral Drug Approved
The South African Health Products Regulatory Authority (SAHPRA) has approved Cipla’s latest first-line triple-combination antiretroviral (ARV) treatment for HIV. The new combination medicine commonly referred to as TLD, is a combination of tenofovir (TDF),
lamivudine (3TC) and dolutegravir (DTG).
Cipla partners with MSN Laboratories for marketing and distribution of generic Xeloda® (Capecitabine Tabs 150mg and 500mg)
Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100mg, 150mg, 200mg, 300mg)
Cipla Limited (“Cipla”) today announced that it has received final approval for it's Abbreviated New Drug Application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, 300mg from the United States Food and Drug Administration (US FDA).
